Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Ono5920

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Phase 2/3 (1)
Phase 3 (3)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT02063854Phase 2/3CompletedPrimary

A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets

NCT00212667Phase 3CompletedPrimary

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212719Phase 3CompletedPrimary

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212628Phase 3CompletedPrimary

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Showing all 4 trials

Research Network

Common Treatments

  • Ono59202
  • Ne58095 Dr Placebo1
  • Ne58095 Ir Placebo1
  • Ne58095 Ir1
  • Ne58095 Dr1

Active Sponsors

  • Ono Pharmaceutical Co., Ltd.3
  • Astellas Pharma Inc2
  • Takeda1
  • EA Pharma Co., Ltd.1

Top Investigators

Activity Timeline